Save Product
Product Details
Source
Monoclonal Anti-DXD & Exatecan Antibody, Rabbit IgG (M1B09) is a recombinant rabbit monoclonal antibody expressed in HEK293 cells.
Antibody Type
Recombinant Monoclonal
Clone
M1B09
Isotype
Rabbit IgG, Kappa
Immunogen
DXD-BSA
Specificity
Specifically recognizes the DXd and DXd structurally similar molecules.
Application
ApplicationRecommended UsageELISA1:2000-1:20000Purification
Protein A purified / Protein G purified.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Immobilized Monoclonal Anti-DXD & Exatecan Antibody, Rabbit IgG (M1B09) (Cat. No. DXD-MY2290) at 5 μg/mL, add Trastuzumab Deruxtecan in the 100% Human Serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).
Protocol
Immobilized Monoclonal Anti-DXD & Exatecan Antibody, Rabbit IgG (M1B09) (Cat. No. DXD-MY2290) at 5 μg/mL, add Trastuzumab Deruxtecan in the 0.5% BSA and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).
Protocol
Serial dilutions of DXD were added into Monoclonal Anti-DXD & Exatecan Antibody, Rabbit IgG (M1B09) (Cat. No. DXD-MY2290): Trastuzumab Deruxtecan binding reactions. The half maximal inhibitory concentration (IC50) is 0.05452 μg/mL (Routinely tested).
Protocol
Cross Verification
ELISA binding of Monoclonal Anti-DXD & Exatecan Antibody, Rabbit IgG (M1B09) (Cat. No. DXD-MY2290) with Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecam, Trastuzumab MMAE, Doxorubicin-ADC and IgG1-MMAF conjugated antibody respectively.
The coating antibody was Monoclonal Anti-DXD & Exatecan Antibody, Rabbit IgG (M1B09) (Cat. No. DXD-MY2290), used at 1 μg/mL concentration. The primary antibody were different payload conjugated antibodies, including Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecam, Trastuzumab MMAE, Doxorubicin-ADC and IgG1-MMAF conjugated antibodies used at 0.5 μg/mL concentration. The secondary antibody was HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8), mAb (Acro, Cat. No. IGG-LY69) used at 1:10000 concentration.
Monoclonal Anti-DXD & Exatecan Antibody, Rabbit IgG (M1B09) (Cat. No. DXD-MY2290) is specific to Trastuzumab Deruxtecan, and has no cross-reactivity with Disitamab Vedotin (RC48), Sacituzumab Govitecam, Trastuzumab MMAE, Doxorubicin-ADC and IgG1-MMAF (Routinely tested).
Customer Reviews Writing Reviews
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
